Abstract：
OBJECTIVE: Lymphoma is the sixth most common cancer in Australia and comprises 2.8% of worldwide cancer diagnoses. Research targeting development and evaluation of post-treatment care for debilitating complications resulting from the disease and its treatment is limited. This study aimed to assess the feasibility and acceptability of a nurse-led survivorship intervention, post-treatment in Hodgkin\'s and non-Hodgkin\'s lymphoma survivors.
METHODS: A single-center, prospective, 3-arm, pilot, randomized controlled, parallel-group trial was used. People with lymphoma were recruited and randomized to the intervention (ENGAGE), education booklet only, or usual care arm. Participants receiving ENGAGE received an educational booklet and were offered 3 consultations (via various modes) with a cancer nurse to develop a survivorship care plan and healthcare goals. Participant distress and intervention acceptability was measured at baseline and 12-wk. Acceptability was measured via a satisfaction survey using a 11-point scale. Feasibility was measured using participation, retention rates, and process outcomes. Data were analyzed using descriptive statistics.
RESULTS: Thirty-four participants with HL and NHL were recruited to the study (11 = intervention, 11 = information only, 12 = usual care). Twenty-seven participants (79%) completed all time points from baseline to 12 wk. Seven (88%) of the 8 participants receiving ENGAGE completed all consultations using various modes to communicate with the nurse (videoconference 14/23, 61%; phone 5/23, 22%; face-to-face 4/23, 17%). Participants who completed the intervention were highly satisfied with ENGAGE.
CONCLUSIONS: The ENGAGE intervention is feasible and highly acceptable for lymphoma survivors. These findings will inform a larger trial assessing effectiveness and cost effectiveness of ENGAGE.
METHODS: A single-center, prospective, 3-arm, pilot, randomized controlled, parallel-group trial was used. People with lymphoma were recruited and randomized to the intervention (ENGAGE), education booklet only, or usual care arm. Participants receiving ENGAGE received an educational booklet and were offered 3 consultations (via various modes) with a cancer nurse to develop a survivorship care plan and healthcare goals. Participant distress and intervention acceptability was measured at baseline and 12-wk. Acceptability was measured via a satisfaction survey using a 11-point scale. Feasibility was measured using participation, retention rates, and process outcomes. Data were analyzed using descriptive statistics.
RESULTS: Thirty-four participants with HL and NHL were recruited to the study (11 = intervention, 11 = information only, 12 = usual care). Twenty-seven participants (79%) completed all time points from baseline to 12 wk. Seven (88%) of the 8 participants receiving ENGAGE completed all consultations using various modes to communicate with the nurse (videoconference 14/23, 61%; phone 5/23, 22%; face-to-face 4/23, 17%). Participants who completed the intervention were highly satisfied with ENGAGE.
CONCLUSIONS: The ENGAGE intervention is feasible and highly acceptable for lymphoma survivors. These findings will inform a larger trial assessing effectiveness and cost effectiveness of ENGAGE.
摘要：
目的：淋巴瘤是澳大利亚第六大最常见的癌症，占全球癌症诊断的2.8%。针对疾病及其治疗引起的衰弱性并发症的治疗后护理的开发和评估的研究是有限的。本研究旨在评估护士主导的生存干预的可行性和可接受性。霍奇金和非霍奇金淋巴瘤幸存者的治疗后。
方法：单中心，prospective,三臂，飞行员,随机对照,采用平行组试验.淋巴瘤患者被招募并随机分配到干预（ENGAGE），只有教育小册子，或通常的护理手臂。接受ENGAGE的参与者收到了一本教育手册，并与癌症护士进行了3次咨询（通过各种模式），以制定生存护理计划和医疗保健目标。在基线和12周测量参与者的痛苦和干预可接受性。可接受性是通过使用11分量表的满意度调查来衡量的。可行性是通过参与来衡量的，保留率，和过程结果。数据采用描述性统计分析。
结果：招募了34名HL和NHL参与者（11=干预，11=仅提供信息，12=常规护理)。27名参与者（79％）完成了从基线到12周的所有时间点。接受ENGAGE的8名参与者中有7名（88％）使用各种模式与护士进行交流完成了所有咨询（视频会议14/23，61％；电话5/23，22％；面对面4/23，17％）。完成干预的参与者对ENGAGE非常满意。
结论：ENGAGE干预对于淋巴瘤幸存者是可行且高度可接受的。这些发现将为更大的试验评估ENGAGE的有效性和成本效益提供信息。
方法：单中心，prospective,三臂，飞行员,随机对照,采用平行组试验.淋巴瘤患者被招募并随机分配到干预（ENGAGE），只有教育小册子，或通常的护理手臂。接受ENGAGE的参与者收到了一本教育手册，并与癌症护士进行了3次咨询（通过各种模式），以制定生存护理计划和医疗保健目标。在基线和12周测量参与者的痛苦和干预可接受性。可接受性是通过使用11分量表的满意度调查来衡量的。可行性是通过参与来衡量的，保留率，和过程结果。数据采用描述性统计分析。
结果：招募了34名HL和NHL参与者（11=干预，11=仅提供信息，12=常规护理)。27名参与者（79％）完成了从基线到12周的所有时间点。接受ENGAGE的8名参与者中有7名（88％）使用各种模式与护士进行交流完成了所有咨询（视频会议14/23，61％；电话5/23，22％；面对面4/23，17％）。完成干预的参与者对ENGAGE非常满意。
结论：ENGAGE干预对于淋巴瘤幸存者是可行且高度可接受的。这些发现将为更大的试验评估ENGAGE的有效性和成本效益提供信息。
